These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
277 related items for PubMed ID: 32338423
1. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. Abou-Ismail MY, Vuyyala S, Prunty J, Schmaier AH, Nayak L. Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423 [Abstract] [Full Text] [Related]
2. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A. Bowyer A, Shepherd F, Platton S, Guy S, Kitchen S, Maclean R. Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894 [Abstract] [Full Text] [Related]
3. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Haemophilia; 2017 Jan; 23(1):25-32. PubMed ID: 27511890 [Abstract] [Full Text] [Related]
4. Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A. Seki Y, Ogawa Y, Kikuchi T, Sakaida E, Mizuta Y, Kitagawa T, Takemura K, Miyaguchi Y, Nogami K, Matsushita T. Int J Hematol; 2024 Oct; 120(4):482-491. PubMed ID: 39158833 [Abstract] [Full Text] [Related]
5. Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Bowyer A, Gray E, Lowe A, Murphy P, Platton S, Riddell A, Chowdary P, Lester W, Jenkins PV. Haemophilia; 2022 May; 28(3):515-519. PubMed ID: 35279922 [Abstract] [Full Text] [Related]
6. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. Barrow RT, Lollar P. J Thromb Haemost; 2006 Oct; 4(10):2223-9. PubMed ID: 16856973 [Abstract] [Full Text] [Related]
12. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B. Haemophilia; 2015 Mar 22; 21(2):162-170. PubMed ID: 25623166 [Abstract] [Full Text] [Related]
13. Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single-arm, open-label study. Pfrepper C, Radossi P, Windyga J, Kavakli K, Schutgens R, Sarper N, Gu J, Badejo K, Jain N. Haemophilia; 2024 Mar 22; 30(2):395-403. PubMed ID: 38317504 [Abstract] [Full Text] [Related]
14. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab. Pfrepper C, Klamroth R, Ettingshausen CE, Petros S, Siegemund A, Siegemund T. Haemophilia; 2024 Mar 22; 30(2):545-553. PubMed ID: 38343119 [Abstract] [Full Text] [Related]
19. Susoctocog-alfa (Obizur®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. Zanon E, Pasca S, Borchiellini A, Lodigiani C, Molinari AC, Ambaglio C, Valeri F, Preti PS, Moscatelli P, Simioni P. Blood Transfus; 2020 Jul 22; 18(4):312-321. PubMed ID: 32698943 [Abstract] [Full Text] [Related]
20. Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review. Sella C, Bardetta M, Valeri F, Dainese C, Valpreda A, Massaia M, Grimaldi D, Porreca A, Bruno B, Borchiellini A. J Clin Med; 2023 Jul 10; 12(14):. PubMed ID: 37510704 [Abstract] [Full Text] [Related] Page: [Next] [New Search]